Literature DB >> 20410527

Refocusing the war on cancer: the critical role of personalized treatment.

Anil Potti1, Richard L Schilsky, Joseph R Nevins.   

Abstract

Despite very substantial investment and effort over the past 30 years, the overall survival rate of cancer patients has changed little. We propose that without a truly robust mechanism for selecting the right treatment for the right patient at the right time-the central concepts of personalized medicine-we will continue to see only incremental improvements and have little hope for substantial survival gains. We suggest that it is now imperative that future clinical trials be designed with a plan to incorporate biomarker development.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20410527     DOI： 10.1126/scitranslmed.3000643

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  10 in total

1.  Personalized medicine: challenge and promise.

Authors:  Judith Salmon Kaur; Daniel G Petereit
Journal:  J Cancer Educ       Date:  2012-04       Impact factor: 2.037

Review 2.  Sense and nonsense in the process of accreditation of a pathology laboratory.

Authors:  Elodie Long-Mira; Kevin Washetine; Paul Hofman
Journal:  Virchows Arch       Date:  2015-09-03       Impact factor: 4.064

Review 3.  Philanthropic partnerships and the future of cancer research.

Authors:  Yonina R Murciano-Goroff
Journal:  Nat Rev Cancer       Date:  2014-12-04       Impact factor: 60.716

4.  Personalized therapy for pancreatic cancer: Myth or reality in 2010?

Authors:  Tzu-Chuan Jane Huang; Siddhartha Kar; Milind Javle
Journal:  J Gastrointest Oncol       Date:  2010-09

Review 5.  Intracellular delivery of RNA-based therapeutics using aptamers.

Authors:  Kristina W Thiel; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2010-12

6.  Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.

Authors:  Craig J Galbán; Thomas L Chenevert; Charles R Meyer; Christina Tsien; Theodore S Lawrence; Daniel A Hamstra; Larry Junck; Pia C Sundgren; Timothy D Johnson; Stefanie Galbán; Judith S Sebolt-Leopold; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2011-04-28       Impact factor: 12.531

Review 7.  Epigenetics advancing personalized nanomedicine in cancer therapy.

Authors:  Shujun Liu
Journal:  Adv Drug Deliv Rev       Date:  2012-08-19       Impact factor: 15.470

8.  Cancer, inflammation, and insights from ayurveda.

Authors:  Venil N Sumantran; Girish Tillu
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-04       Impact factor: 2.629

9.  Dendrimers for siRNA Delivery.

Authors:  Swati Biswas; Vladimir P Torchilin
Journal:  Pharmaceuticals (Basel)       Date:  2013-02-04

10.  Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.

Authors:  Dominiek Smeets; Ian S Miller; Darran P O'Connor; Sudipto Das; Bruce Moran; Bram Boeckx; Timo Gaiser; Johannes Betge; Ana Barat; Rut Klinger; Nicole C T van Grieken; Chiara Cremolini; Hans Prenen; Massimiliano Mazzone; Jeroen Depreeuw; Orna Bacon; Bozena Fender; Joseph Brady; Bryan T Hennessy; Deborah A McNamara; Elaine Kay; Henk M Verheul; Neerincx Maarten; William M Gallagher; Verena Murphy; Jochen H M Prehn; Miriam Koopman; Cornelis J A Punt; Fotios Loupakis; Matthias P A Ebert; Bauke Ylstra; Diether Lambrechts; Annette T Byrne
Journal:  Nat Commun       Date:  2018-10-05       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.